Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 593 - 600 of 12089 results
‘A Pro Bono Pioneer’
October 11, 2024| News
F-Reorgs: How Buyers’ and Sellers’ Favorite ‘F Word’ Optimizes M&A and Private Equity Transactions Involving S Corporations
October 10, 2024| Alert| Viewpoint
'Spycraft' by Employers Raising Alarm as Technology Advances
October 10, 2024| News
Plaintiff's Non-compete Play 'Gives Pro-business Fans Reason to Celebrate'
October 10, 2024| News
Private Equity: How to Stay Out of the DOJ’s Cross-Hairs
October 10, 2024| News
In-House Leaders Trying to Contain Political Divisiveness Face Maze of Challenges
October 10, 2024| News
OHRP Workshop Highlights Artificial Intelligence Uses, Concerns in Human Research
October 9, 2024| Blog| Viewpoint
Contemplating the Impact of the USPTO’s AI-Focused Patent Eligibility Guidance on Networking Applications
October 9, 2024| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|